[{"id":"pulsar-bcva","name":"Change in BCVA at Week 48","type":"PRIMARY","unit":"letters","results":[{"notes":"Non-inferior to EYLEA 2mg Q8W","value":8,"arm_id":"eyleahd-q12-pulsar","arm_name":"EYLEA HD Q12W"},{"notes":"Non-inferior to EYLEA 2mg Q8W","value":7.6,"arm_id":"eyleahd-q16-pulsar","arm_name":"EYLEA HD Q16W"},{"value":8.7,"arm_id":"eylea-q8w-pulsar","arm_name":"EYLEA 2mg Q8W"}],"timepoint":"Week 48","description":"Mean change from baseline in best-corrected visual acuity (ETDRS letters) at Week 48. Non-inferiority of EYLEA HD extended dosing vs EYLEA 2mg Q8W."}]

PULSAR met primary endpoint: EYLEA HD Q12W (+8.0 letters) and Q16W (+7.6 letters) were non-inferior to EYLEA 2mg Q8W (+8.7 letters). 79% of Q16W patients maintained the extended interval — meaning only 4 injections/year vs 6-7 with EYLEA 2mg.

PULSAR (n=1009, 48 weeks): Similar safety to EYLEA 2mg. Conjunctival hemorrhage 13%, eye pain 5%, vitreous floaters 6%. No new safety signals with 8mg dose.

PULSAR is the biosimilar defense strategy. EYLEA HD enables Q16W dosing (79% of patients = 4 injections/year). Biosimilar EYLEA 2mg requires Q8W (7 injections/year). Retina docs will prefer the branded product that cuts injection burden in half. This buys REGN several years of franchise protection.

Higher aflibercept dose (8mg vs 2mg) enables extended dosing intervals. Key for patient compliance and clinic burden.